What Is the Maximum Safe Dose of Opioids? - Medscape
Feb 21, 2008 · Charts and tables are readily available from multiple sources that attempt to correlate certain doses of oxycodone to other opioid narcotics. "Maximum safe dose" is patient …
Latest Medical News, Clinical Trials, Guidelines - Today on Medscape
2 days ago · Today on Medscape : Get the latest medical news, clinical trial coverage, drug updates, journal articles, CME activities & more on Medscape. A free resource for physicians.
Should Patients With Thyroid Issues Take GLP-1s? It Depends
Dec 19, 2024 · Obesity and family practice experts share when it’s safe to prescribe GLP-1 receptor agonists to patients with thyroid problems and what conditions should preclude the …
Nurses - Medscape
5 days ago · Nurses : Welcome to Medscape Nurses, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles, …
Doxycycline Postexposure Prophylaxis (Doxy PEP): 5 Things to Know
Jan 17, 2025 · In 2024, the Centers for Disease Control and Prevention (CDC) released guidelines [1] for the recommended use of doxycycline postexposure prophylaxis (Doxy PEP) …
When Can Controlled Substances Be Refilled Early? - Medscape
Sep 23, 2011 · Anytime when a pharmacist dispenses medication, particularly controlled substances, the pharmacist must be vigilant to ensure that it is for a "legitimate medical purpose."
NSAIDs Linked to Increased Venous Thromboembolism Risk
Sep 25, 2014 · The pooled risk ratio among NSAID users was 1.8-fold for VTE (95% confidence interval, 1.28 - 2.52). Among participants who used selective cyclooxygenase 2 (COX-2) …
Why Should Nitrofurantoin Be Avoided in the Elderly? - Medscape
May 10, 2013 · Besides the potential subtherapeutic effect of nitrofurantoin in patients with renal impairment, patients may be at increased risk for adverse events secondary to drug …
Cardiology Perspective - Index - Medscape
Apr 18 2025 This Week in Cardiology The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses …
Dupilumab Under FDA Priority Review for Bullous Pemphigoid
Feb 20, 2025 · Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a …